Abstract: A composition and method adapted for the treatment of ischemic brain injury is disclosed, which includes applying hypothermic conditions to a subject within 5 hours after onset of brain injury and administering to the subject in need thereof a dose of a pharmaceutically effective amount of caffeine and at least a pharmaceutically effective amount of an alcohol or mixtures thereof adapted for the treatment of cerebral ischemia under hypothermic conditions.

Abstract: A composition and method for the treatment of cerebral ischemia is disclosed, the composition is a mixture of caffeine and alcohol and is used to treat cerebral ischemia by administering to a subject in need thereof a dose of an effective amount of caffeine and at least a effective amount of an alcohol or mixtures thereof.

Abstract: The invention is directed to uses of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment and prevention of cellular abnormalities of the lung or bronchial pathway.

Abstract: The invention is directed to uses of non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment and prevention of cellular abnormalities of the female reproductive tract.

Abstract: A composition and method for the treatment of cerebral ischemia is disclosed, the composition is a mixture of caffeine and alcohol and is used to treat cerebral ischemia by administering to a subject in need thereof a dose of an effective amount of caffeine and at least a effective amount of an alcohol or mixtures thereof.

Abstract: Pharmaceutical and cosmetic preparations containing pyrogenic silicon dioxide with a tamped density of 80-250 g/l. Preparations and compositions as solid, semisolid and liquid forms. Products, such as cosmetics, and methods of treatment using such compositions.

Abstract: A physiologically acceptable aqueous solution, and water-soluble compositions suitable for obtaining it, comprising a first physiologically acceptable compound of an acidic nature and a second physiologically acceptable compound of a basic nature that are able to give rise to a precipitate in water, characterized in that it also contains a trisubstituted salt of glycyrrhizic acid in a sufficient quantity to form a clear solution in water.

Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed. The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.

Abstract: Methods for treating or modulating inflammatory processes or chronic inflammatory conditions dependent upon cellular inflammation, such as asthma and rheumatoid arthritis are provided, as well as methods for inhibiting or blocking eosinophil migration and airway hyperresponsiveness. Also described is a method for treating or preventing the adhesion of granulocytes and other inflammatory cells into the tissue that is the site of the inflammation. In particular, the methods relate to the therapeutic or prophylactic use of compounds and compositions that inhibit cytosolic phospholipase A2.

Abstract: One aspect of the invention relates to anti-viral composition containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients such as at least one analgesic) at least one hydrocarbyl containing compound, and water. Another aspect of the invention relates to a method of treating lesionous symptoms of a viral infection involving applying an effective amount of the zinc containing anti-viral composition to the lesions.

Abstract: A composition for treating acneiform eruption containing: (a) a chitosan having a molecular weight ranging from about 500,000 to about 5,000,000 g/mole and a degree of deacylation greater than 80%; (b) an acid-form active ingredient for treating acne; and (c) water.

Abstract: The present invention provides a method for treating pain using an atypical antipsychotic compound.

Abstract: Ibuprofen-aspirin compounds useful in treating aspirin or ibuprofen-treatable conditions and hydroxymethylacylfulvene analogs useful as antitumor drugs.

Abstract: In one embodiment, the invention relates to sustained-release compositions comprising one or more prolamins, one or more gelling agents, and one or more active agents. Such compositions are particularly useful for controlled delivery of high solubility and/or high dosage active agents. In another embodiment, the present invention relates to delayed-onset compositions comprising a dry coating comprising one or more prolamins and one or more gelling agents.

Abstract: An anti-inflammatory, either a NSAID or glucocorticoid steroid in the form of an ointment, cream, lotion, gel, powder, tablet, paste, film, tape or adhesive bandage, provided with appropriate vehicle to allow specific adherence to specific gingival areas, for topical treatment of inflammation. This composition and the method of using same is used to prevent or relieve migraine, tension-type headache, post-traumatic headache, facial pain and cervical muscle spasm.

Abstract: The present invention relates to stable salts of O-acetylsalicylic acid with basic amino acids, a process for their preparation and their use as medicaments.

Abstract: According to the invention, compositions are made available which have a strong cytotoxic effect which is largely selective on tumor tissue. The invention is based on the fact that certain benzoic acid derivatives have a strong synergistic effect as a mixture and destroy cancer cells selectively in a pH range of 7 or below, such as from 6.5 to 7.

Abstract: The invention relates to antagonists of CX3C chemokine receptor 1 (CX3CR1) function, antagonists of fractalkine function and to therapeutic methods employing the antagonists. The invention also relates to a method for diagnosing rheumatoid arthritis.

Abstract: This invention is directed to a method of retarding or preventing the transformation of a colonic adenoma to a colonic adenocarcinoma comprising the administration to a patient with FAP or a patient with one or more of said adenomas a non-toxic therapeutically effective amount of NSAID, said amount effective to inhibit the PGHS-2 in said adenoma. The preferred method comprises the administration of a specific PGHS-2 inhibiting agent as defined herein.

Abstract: A contact lens having a pharmaceutical agent releasably disposed therein. The lens itself comprises a polymer of an unsaturated carboxylic acid ester of salicylic acid, the unsaturated carboxylic acid having up to 24 carbon atoms and 1-4 ethylenic double bonds, or a pharmaceutically acceptable salt of the salicylic acid ester.

Abstract: Methods for preventing or ameliorating the transient adverse physiological response to particulate dispersions (TAPR response) when these dispersions are administered parenterally to a patient. The methods comprise the administration of a prophylactic anti-inflammatory drug prior to administration of the particulate-containing material, and optionally during administration as well. Preferred drugs are cyclooxygenase inhibitors and corticosteroids.

Abstract: The present invention provides methods for treating subjects having or at risk of having a neuropathological disorder or brain inflammatory diseases with and without vascular involvement, and systemic inflammatory vascular disease by administering a therapeutically effective amount of Activated Protein C (APC) to the subject. Brain disorders and brain inflammatory vascular diseases that can be treated by the invention method include all neurodegenerative diseases with different types of neuronal dysfunction, including stroke, Alzheimer's disease, Parkinson's disease, Huntington disease, neuroimmunological disorders such as multiple scelrosis and Gullian-Barre, encephalitis, meningitis, as well as other peripheral vascular diseases, such as diabetes, hypertension, artheriosclerosis. Also included are methods of treatment using APC in combination with a co-factor, such as Protein S.

Abstract: Disclosed are compounds having a scytoneman skeleton, such as scytonemin, and methods of using thereof. Methods of using a compound having a scytoneman skeleton to inhibit, modulate, attenuate, or prevent cell-cycle progression, cell proliferation, kinase activity, or induce apoptosis are disclosed. Also disclosed are methods of treating, preventing, or inhibiting diseases and disorders associated with cell cycle progression, cell proliferation, kinase activity, tissue hyperplasia or angiogenesis, such as cancer or an inflammatory disease.

Abstract: The invention relates to the use of cocoa procyanidins in combination with an aspirin as an anti-platelet therapy and compositions comprising cocoa procyanidins and aspirin (acetylsalicyclic acid).

Abstract: The present invention relates to compositions, methods and kits for improving the size and appearance of a healed wound or scar. The composition includes a therapeutically effective amount of at least one cyclooxygenase inhibitor, NF-kB inhibitor, or an antiirritant. For topical, transdermal administration, the cyclooxygenase inhibitor or NF-kB inhibitor may be present in a thermal insulating material such as a hydrogel. The thermal insulating material may also include a deodorant agent to reduce surface bacteria and odor formation.

Abstract: Disclosed is the method of reducing the incidence and severity of stroke, primary heart attack, and any subsequent heart attack or stroke in humans by daily administration of an effective amount of a combination of acetylsalicylic acid (ASA),a cyanocobalamin compound (Vitamin B12), a folic acid compound, and a pyridoxine compound (Vitamin B6) in an easy to take daily administration pack.

Abstract: In a method for producing stable acetylsalicylic acid solutions with pharmaceutically acceptable non-aqueous organic solvents such as, e.g., dimethylisosorbide, propylene glycol or diethylene glycol monoethyl ether, 0.005-2% by weight of a cyclic acid imide and/or 0.005-2% by weight of a sulfaminic acid as well as, preferably, 1-40% by weight, based on the weight of the solution, of a compound of the general formula are added to the solution. In the general formula, R1 represents H, CH3 or C2H5, n=0 or 1, and R2 represents H or one or more lower alkyl, lower alkyloxy or lower alkenyl residues having 1 to 5 carbon atoms.

Abstract: Compositions and methods of the topical treatment of equine laminitis are disclosed. In particular, combinations of a fast acting nitric oxide (NO) donor, a sustained acting NO donor and an NSAID mixed in a lipid-based carrier are described. The application of such combinations to the affected areas, e.g., the hoofs and surrounding tissues, of an equine afflicted with laminitis provides relief from the debilitating effects of this painful, often life-threatening condition.

Abstract: External preparations containing Aspirin which are stored for a long term and superior in dermal absorbability. The preparations are prepared by mixing Aspirin together with at least one substance selected from an ester of an organic acid ester having 2 to 20 carbon atoms, a glycerol fatty acid ester, silicon oil, hydrocarbon oil and crotamiton.

Abstract: A method for preventing adverse effects associated with the use of a medical device in a patient by introducing into the patient a device of which at least a portion includes a prophylactic or therapeutic amount of a nitric oxide adduct. The nitric oxide adduct can be present in a matrix coating on a surface of the medical device; can be coated per se on a surface of the medical device; can be directly or indirectly bound to reactive sites on a surface of the medical device; or at least a portion of the medical device can be formed of a material, such as a polymer, which includes the nitric oxide adduct. Also disclosed is a method for preventing adverse effects associated with the use of a medical device in a patient by introducing the device during a medical procedure and before or during said procedure locally administering a nitric oxide adduct to the site of contact of said device with any internal tissue.

Abstract: A method of treating a disease of condition administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage comprising a therapeutically effective amount of a drug to treat said disease or condition and a form of hyaluronic acid characterized in that the composition is immediately available to transport the drug percutaneously into the epidermis of the skin or exposed tissue to the site of trauma or pathology of the disease or condition to be treated.

Abstract: The invention provides compositions and methods for treatment of narcolepsy or isolated cataplexy. Such methods entail administering a therapeutically effective regime of at least one immunosuppressive agent. The methods are particularly useful for prophylactic and therapeutic treatment of narcolepsy or isolated cataplexy.

Abstract: A daily nutritional supplement and method of administering it to assist in the metabolism of glucose for patients with diabetes and pre-diabetes is disclosed. The supplement preferably includes anchor components of Chromium Polynicotinate and Picolinate, Vanadyl Sulfate, Vitamin E Natural, Standardized Willow Bark (aspirin), and Magnesium Chloride, Citrate, Fumarate, Malate, Glutorate, and Succinate Complex, Folic Acid, and Alpha-Lipoic Acid.

Abstract: Methods are disclosed for treating neurotransmitter-mediated pain syndromes such as fibromyalgia. Such methods include topically administering an effective amount of a composition containing an omega fatty acid in combination with a carrier or diluent. The composition may also contain a cyclo-oxygenase inhibitor and other optional components, such as vitamins A, E and/or C.

Abstract: An oily composition having excellent storability and forming no precipitate of an ingredient selected from the group of gelatin and gum arabic during the storage for a long period of time is provided. This composition is composed of a solid phase comprising an effective substance selected from the group consisting of a water-soluble substance and water-dispersible substance and 50 to 4,000 parts by weight, for 100 parts by weight of the effective substance, of the ingredient, and an oil phase comprising an oily component and an emulsifier, wherein the solid phase in the form of fine particles having an average particle diameter of not larger than 5 &mgr;m is dispersed in the oil phase, the water content of the solid phase is not higher than 30% by weight and the water content of the whole composition is not higher than 20% by weight.

Abstract: Starburst conjugates which are composed of at least one dendrimer in association with at least one unit of a carried agricultural, pharmaceutical, or other material have been prepared. These conjugates have particularly advantageous properties due to the unique characteristics of the dendrimer.

Abstract: Compositions for the treatment and prevention of migraine or stress headaches wherein there is supplied a combination of potassium, magnesium and pyridoxine optionally in association with other nutrients and/or simple analgesics.

Abstract: A method of preventing or delaying the onset of symptoms of Alzheimer's Disease includes the step of administering to a patient in need of such treatment a composition having an effective Alzheimer's Disease prophylactic amount of an enantiomerically stable R-NSAID or a pharmaceutically acceptable salt thereof, the composition being substantially free of the S-enantiomer of the selected R-NSAID.

Abstract: Topical compositions and methods are disclosed for the treatment of pseudofolliculitis barbae and ingrown hair. The compositions comprise acetylsalicylic acid, propylene glycol, glycerine, and isopropyl alcohol. The method involves the step of applying the composition to the beard areas of the face after shaving. The acetylsalicylic acid is dissolved in a solvent mixture comprising propylene glycol, glycerine, and isopropyl alcohol. The acetylsalicylic acid is present in the range of between about 5 percent by weight per unit volume of the solvent mixture up to saturation of the solvent mixture. The solvent mixture comprises propylene glycol in the range of about 5 to 15 percent by volume, glycerine in the range of about 1 to 10 percent by volume, and the balance of the volume made up with isopropyl alcohol alone or a solution comprising at least 50 percent by volume of isopropyl alcohol.

Abstract: The invention provides a method for treating, preventing, or reducing the risk of developing a condition selected from the group consisting of acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke, in a patient, comprising administering to the patient a therapeutically effective amount of an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and an antiplatelet agent, or a pharmaceutically acceptable salt thereof.

Abstract: A method of treating a disease or condition comprising administering topically to the skin or exposed tissue of a human, a dosage amount of a pharmaceutical composition, said dosage comprising a therapeutically effective amount of a drug to treat said disease or condition and a form of hyaluronic acid characterized in that the composition is immediately available to transport the drug percutaneously into the epidermis of the skin or exposed tissue to the site of trauma or pathology of the disease or condition to be treated.

Abstract: Compositions for the relief of pain containing acetyl salicylic acid or acetaminophen as a peripherally acting analgesic and codeine as a centrally acting agent.

Abstract: Disclosed is the method of reducing the incidence and severity of atherosclerosis, atherosclerotic central nervous system disease, claudication, coronary artery disease, homocystine related disorders, hypertension, peripheral vascular disease, presenile dementia and/or restenosis in humans by daily administration of an effective amount of a combination of acetylsalicylic acid (ASA), at least one antioxidant, a cyanocobalamin compound (Vitamin B12), a folic acid compound, a pyridoxine compound (Vitamin B6) and a niacin compound.

Abstract: The invention provides the use of a cycloaygenase inhibitor such as the non-steroidal anti-inflammatory agent aspirin in the manufacture of a medicament to enhance perfusion of blood through the mammalian, preferably human, uterus.

Abstract: A method is disclosed for inducing thromboxane suppression in a mammalian subject by percutaneously administering a pharmaceutical composition containing aspirin. Articles useful for practicing the therapeutic methods of the invention are also disclosed.

Abstract: Non-steroidal anti-inflammatory drugs proved to be effective drugs for combating and preventing asthma if administered by inhalation. Useful are for instance acetylsalicylic acid, and indomethacin, and ketoprofen, and tenoxicam. Suitable pharmaceutical compositions for inhalation are aerosols with a particle size of from 0.5 .mu.m to 7 .mu.m which enter the compartments of the lungs. Aqueous or aqueous-organic solutions or suspensions can be nebulized in combination with propelling agents, or mixtures of powders with microfine drugs can be administered using inhalers. These pharmaceutical compositions may comprise appropriate additives, in order to improve their relevant pharmaceutical properties.

Abstract: Compositions and methods of the topical treatment of equine laminitis are disclosed. In particular, combinations of a fast acting nitric oxide (NO) donor, a sustained acting NO donor and an NSAID mixed in a lipid-based carrier are described. The application of such combinations to the affected areas, e.g., the hoofs and surrounding tissues, of an equine afflicted with laminitis provides relief from the debilitating effects of this painful, often life-threatening condition.

Abstract: Nonsteroidal antiinflammatory drugs which have been substituted with a nitrogen monoxide group; compositions comprising (i) a nonsteroidal antiinflammatory drug, which can optionally be substituted with a nitrogen monoxide group and (ii) a compound that directly donates, transfers or releases a nitrogen monoxide group (preferably as a charged species, particularly nitrosonium); and methods of treatment of inflammation, pain, gastrointestinal lesions and/or fever using the compositions are disclosed The compounds and compositions protect against the gastrointestinal, renal and other toxicities that are otherwise induced by nonsteroidal antiinflammatory drugs.

Abstract: The present invention relates to a biodegradable plastic made from a combination of at least one synthetic plastic polymer, at least one natural polymer and a natural polymer attacking agent and articles made therefrom.The present invention further relates to a method of eliminating hydrocarbon contaminating a region subjected to extreme temperatures by contacting the region with hydrocarbon-degrading microorganisms and adjusting the temperature of the region for optimum growth.The present invention also relates to a method of treating aspirin-treatable conditions comprising administering to a patient in need of such treatment a compound of Formula I ##STR1## In addition, the present invention relates to a method of protecting a philatelic item bearing a mark identifying an expert or owner of the item and possibly an additional distinguishable mark specific to the philatelic item from alteration.

Abstract: The present invention relates, in general, to a method of preventing or delaying the onset of Alzheimer's disease and related neurodegenerative disorders. The invention also relates to a method of treating Alzheimer's disease and related neurodegenerative disorders so as to ameliorate the further progress of symptoms. The methods involve the administration of a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor blocking agent. According to indication, the present method can be applied to individuals who are currently asymptomatic but at risk of developing Alzheimer's disease, to individuals who have mild cognitive symptoms that may either denote an incipient prodrome of Alzheimer's disease or represent early symptoms (prodromal stage), or to individuals who have a clinical diagnosis of Alzheimer's disease.